Staar Surgical Company (STAA) just got a significant regulatory boost that could reshape its business trajectory. The FDA approved an expanded age indication for the company's EVO/EVO+ Visian Implantable Collamer Lenses on Tuesday, extending eligibility from patients aged 21-45 to those aged 21-60. That's not just a numbers tweak—it potentially brings nearly 8 million additional refractive patients into the fold.
The approval came on the heels of three-year clinical trial safety data that reinforced what Staar has been arguing all along: these lenses have a solid long-term safety profile. And the market seems to like it, with shares trading higher in premarket action Wednesday.
The Great LASIK Shift
Here's where it gets interesting. The vision correction market is going through a quiet transformation. In the U.S., EVO ICL has become the dominant procedure for patients with higher degrees of nearsightedness (specifically -8.0 diopters and above), even as laser-based procedures are seeing significant declines. Recent studies show that more than half of American vision correction consumers are now interested in alternatives to LASIK, signaling a genuine shift in how people think about fixing their eyesight.
The appeal makes sense when you understand the procedure. EVO lenses are implanted through a quick, minimally invasive surgery where the lens sits behind the iris but in front of your natural lens. For many patients, especially those with more severe vision problems, it offers a solution that laser procedures simply can't match.
Safety By The Numbers
The FDA clinical trial tracked 629 eyes over three years, and the results paint a reassuring picture. The safety index came in at 1.25 at the three-year mark, there were zero reported cases of pupillary block or pigment dispersion, and anterior subcapsular cataract showed up in just 0.16% of cases. Those are the kinds of numbers that get regulators comfortable expanding approvals.
Corporate Drama in the Background
Of course, this good news arrives against a backdrop of significant corporate turbulence. Back in January, Staar's proposed merger with Alcon Inc. (ALC) fell apart after shareholders voted against the deal at a special meeting. The companies terminated the agreement, leaving Staar to chart its own course.
Following that rejection, the company's board got a makeover. Neal Bradsher and Richard LeBuhn from Broadwood Partners, along with Christopher Wang from Yunqi Capital, joined the board through a cooperation agreement. Broadwood, notably, is Staar's largest shareholder, so this wasn't just any board addition—it represented a meaningful shift in governance.
What The Charts Say
Technically speaking, the stock is showing some concerning patterns. It's trading 9.8% below its 20-day simple moving average and a substantial 29.8% below its 100-day SMA, signaling bearish momentum in both the short and medium term. Over the past year, shares have slipped 2.59% and are sitting much closer to their 52-week lows than highs.
That said, the RSI reading of 22.35 puts the stock firmly in oversold territory, suggesting it may be undervalued at current levels. Meanwhile, the MACD remains below its signal line, confirming continued bearish pressure. It's a mixed technical picture—oversold but still trending negative.
- Key Resistance: $18.50
- Key Support: $14.50
Looking Ahead to Earnings
Investors won't have to wait long for the next catalyst. Staar Surgical reports earnings on March 3, 2026, and analysts are expecting a significant improvement:
- EPS Estimate: 12 cents (compared to a loss of 69 cents in the year-ago period)
- Revenue Estimate: $75.25 million (up from $48.95 million)
The analyst community remains cautious but not entirely pessimistic. The consensus rating sits at Hold with an average price target of $27.30, implying substantial upside from current levels. Recent analyst actions show the range of opinions:
- Stifel: Hold rating (lowered target to $19)
- Wedbush: Initiated coverage with Neutral (target $26)
- Jefferies: Buy rating (lowered target to $21.50)
ETF Exposure Worth Noting
For investors looking at indirect exposure, the SPDR S&P Health Care Equipment ETF (XHE) holds Staar as 2.84% of its portfolio, making it the most concentrated ETF position for the stock.
As of Wednesday's premarket session, Staar Surgical shares were up 2.28% to $16.57, reflecting initial investor enthusiasm for the FDA's expanded approval. Whether this regulatory win can help the company break out of its recent technical malaise remains to be seen, but it's certainly a step in the right direction for a company navigating both market shifts and internal changes.
